Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration.

ABSTRACT: Individualized treatment regimens may reduce patient burden with satisfactory patient outcomes in neovascular age-related macular degeneration. Intravitreal anti-VEGF drugs are the current gold standard. Fixed monthly injections offer the best visual outcome but this regimen is not commonly followed outside clinical trials. A PRN regimen requires monthly visits where the patient is treated in the presence of signs of lesion activity. Therefore, an early detection of reactivation of the disease with immediate retreatment is crucial to prevent visual acuity loss. Several trials suggest that "treat and extend" and other proactive regimens provide a reasonable approach. The rationale of the proactive regimens is to perform treatment anticipating relapses or recurrences and therefore avoid drop

SUBMITTER: Garcia-Layana A 

PROVIDER: S-EPMC4600506 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature